# A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

> **NCT02042885** · PHASE1,PHASE2 · TERMINATED · sponsor: **Otsuka Novel Products GmbH** · enrollment: 79 (estimated)

## Conditions studied

- Prostate Cancer
- Salivary Gland Cancer
- Endometrial Cancer
- Squamous Cell Carcinoma of the Cervix
- Breast Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** OPB-111001

## Key facts

- **NCT ID:** NCT02042885
- **Lead sponsor:** Otsuka Novel Products GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042885, "A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02042885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*